EUVIMEDEUVIMED entdecken
Crossref

Association of BRAF V600E Allele Frequency With Clinicopathologic Outcomes in Papillary Thyroid Cancer

Max A Schumm iD, Yuri E Nikiforov iD, Marina N Nikiforova iD, Abigail I Wald, Chi-Hong Tseng iD, Stephanie Smooke-Praw iD, James X Wu iD, Michael W Yeh iD, Masha J Livhits iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae774 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Max A Schumm und 8 weiteren Autor:innen. Beteiligte Einrichtung: Section of Endocrine Surgery, Department of Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Thyroid Cancer, Papillary, Thyroid Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Garry Shandling estate (MW), Omaze (MW).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

BRAF V600E mutation is the most common genetic driver of papillary thyroid cancer (PTC), where it is found with various allele frequency (AF), reflecting the proportion of cells carrying the mutant and wild-type gene alleles.

Objective

To determine whether BRAF V600E AF can improve prognostication and inform initial surgical management of PTC.

Methods

This retrospective cohort study (2016-2019) at UCLA Health included consecutive patients with Bethesda V/VI nodules and isolated BRAF V600E mutation who underwent surgery with histopathology showing PTC. Blinded ThyroSeq v3 molecular analysis was conducted after completion of initial management and follow-up. The risk of aggressive histopathology and cancer persistence/recurrence were assessed.

Results

Of 73 patients, the median BRAF V600E AF was 25.5% (IQR, 16.7%-34.3%). Higher median AF was seen in patients classified as American Thyroid Association high-risk (37%) vs intermediate-risk (25.3%, P < .01) and low-risk (24.7%, P < .01), largely attributed to higher AF in patients with gross extrathyroidal extension (ETE) (40.1% vs 25.2% without gross ETE, P = .02). No differences in AF were observed on the basis of lymph node positivity or presence of aggressive variants of PTC. A higher BRAF V600E AF was also found in patients with tumors ≥ 2 cm vs < 2 cm (median 32.0% vs 24.4%, P < .01). Over 4.1 years of follow-up, disease persistence/recurrence was found in 7 patients (9.4%) and was associated with higher median AF than those without recurrence (35.3% vs 25.2%, P = .02). Higher AF was associated with poorer recurrence-free survival (AF ≥ 35%; HR 7.40; CI, 1.4-38.1).

Conclusion

Higher AF was associated with gross ETE and increased recurrence risk. This may inform initial management in patients with PTC harboring an isolated BRAF V600E mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafThyroid Cancer, PapillaryThyroid NeoplasmsNeoplasm Recurrence, LocalGene FrequencyHumansMaleFemaleMiddle AgedRetrospective StudiesAdultPrognosisMutationFollow-Up StudiesThyroidectomyAged

Stichwörter der Autor:innen

BRAF V600EPTCallele frequencymolecular testthyroid cancer

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, human

Autor:innen und Institutionen

  • Section of Endocrine Surgery, Department of Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA.
  • Department of Pathology and Laboratory Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
  • Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA.
  • Division of Endocrinology, Diabetes, and Metabolism; Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA.

ORCID-Profile: Max A Schumm, Yuri E Nikiforov, Marina N Nikiforova, Chi-Hong Tseng, Stephanie Smooke-Praw, James X Wu, Michael W Yeh, Masha J Livhits

Förderung

  • Garry Shandling estate (MW)
  • Omaze (MW)

Zitieren

APA

Schumm, M. A., Nikiforov, Y. E., Nikiforova, M. N., Wald, A. I., Tseng, C. H., Smooke-Praw, S., Wu, J. X., Yeh, M. W., & Livhits, M. J. (2025). Association of BRAF V600E Allele Frequency With Clinicopathologic Outcomes in Papillary Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae774

Vancouver

Schumm MA, Nikiforov YE, Nikiforova MN, Wald AI, Tseng CH, Smooke-Praw S, et al. Association of BRAF V600E Allele Frequency With Clinicopathologic Outcomes in Papillary Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae774

BibTeX
@article{Schumm2025,
  author = {Schumm, Max A and Nikiforov, Yuri E and Nikiforova, Marina N and Wald, Abigail I and Tseng, Chi-Hong and Smooke-Praw, Stephanie and Wu, James X and Yeh, Michael W and Livhits, Masha J},
  title = {Association of BRAF V600E Allele Frequency With Clinicopathologic Outcomes in Papillary Thyroid Cancer},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae774}
}
Kostenlos starten →